BACKGROUND: DUROS((R)) delivery technology consists of sterile, nonbiodegradable, single-use devices for continuous, subcutaneous administration of therapeutic molecules at steady rates. DUROS delivery technology is capable of delivering a wide range of therapeutic molecules for durations ranging from 3 to 12 months. Administration of therapy via DUROS devices may facilitate patient compliance with treatment since the DUROS device does not require self-injections. Consistent delivery of drug levels within a targeted therapeutic window achievable with DUROS delivery technology avoids exposure to high initial drug concentrations that can result from bolus injections and that may be associated with certain adverse drug effects. METHODS: Several approaches have been taken to assess the suitability of DUROS devices for delivery of the therapeutic molecules leuprolide acetate, glucagon-like peptide-1 (GLP-1), and omega interferon (omega IFN). Testing includes determining protein stability and measuring in vitro protein release rates. RESULTS: Three peptides or proteins were formulated into either a solution (leuprolide) or Intarcia's proprietary DUROS suspension formulation (GLP-1, omega IFN) and filled into DUROS devices. The devices demonstrated reliable start-up and continuous steady drug delivery in in vitro studies. Stability of the molecules was maintained for 3 years at 37 degrees C (leuprolide), 2 years at 30 degrees C (omega IFN), or 6 months at 37 degrees C (GLP-1). Patients in clinical studies of a 1-year DUROS device found the device to be comfortable and convenient. CONCLUSIONS: Multiple studies demonstrated that peptides or proteins remain stable in DUROS devices and that delivery at a steady rate can be achieved over a wide range of delivery rates.
BACKGROUND: DUROS((R)) delivery technology consists of sterile, nonbiodegradable, single-use devices for continuous, subcutaneous administration of therapeutic molecules at steady rates. DUROS delivery technology is capable of delivering a wide range of therapeutic molecules for durations ranging from 3 to 12 months. Administration of therapy via DUROS devices may facilitate patient compliance with treatment since the DUROS device does not require self-injections. Consistent delivery of drug levels within a targeted therapeutic window achievable with DUROS delivery technology avoids exposure to high initial drug concentrations that can result from bolus injections and that may be associated with certain adverse drug effects. METHODS: Several approaches have been taken to assess the suitability of DUROS devices for delivery of the therapeutic molecules leuprolide acetate, glucagon-like peptide-1 (GLP-1), and omega interferon (omega IFN). Testing includes determining protein stability and measuring in vitro protein release rates. RESULTS: Three peptides or proteins were formulated into either a solution (leuprolide) or Intarcia's proprietary DUROS suspension formulation (GLP-1, omega IFN) and filled into DUROS devices. The devices demonstrated reliable start-up and continuous steady drug delivery in in vitro studies. Stability of the molecules was maintained for 3 years at 37 degrees C (leuprolide), 2 years at 30 degrees C (omega IFN), or 6 months at 37 degrees C (GLP-1). Patients in clinical studies of a 1-year DUROS device found the device to be comfortable and convenient. CONCLUSIONS: Multiple studies demonstrated that peptides or proteins remain stable in DUROS devices and that delivery at a steady rate can be achieved over a wide range of delivery rates.
Authors: J C Wright; S Tao Leonard; C L Stevenson; J C Beck; G Chen; R M Jao; P A Johnson; J Leonard; R J Skowronski Journal: J Control Release Date: 2001-07-10 Impact factor: 9.776
Authors: Victor E Buckwold; Jiayi Wei; Zhuhui Huang; Chunsheng Huang; Aysegul Nalca; Jay Wells; Julie Russell; Barbara Collins; Roger Ptak; William Lang; Curtis Scribner; Dennis Blanchett; Tom Alessi; Peter Langecker Journal: Antiviral Res Date: 2006-09-11 Impact factor: 5.970
Authors: Victor E Buckwold; William Lang; Curtis Scribner; Dennis Blanchett; Tom Alessi; Peter Langecker Journal: Basic Clin Pharmacol Toxicol Date: 2006-07 Impact factor: 4.080
Authors: William R Lykins; Ellen Luecke; Daniel Johengen; Ariane van der Straten; Tejal A Desai Journal: Drug Deliv Transl Res Date: 2017-12 Impact factor: 4.617
Authors: Joseph W Romano; Marc M Baum; Zach R Demkovich; Frank Diana; Charles Dobard; Paul L Feldman; J Gerardo Garcia-Lerma; Alessandro Grattoni; Manjula Gunawardana; Duy-Khiet Ho; Thomas J Hope; Ivana Massud; Mark Milad; John A Moss; Fernanda P Pons-Faudoa; Shane Roller; Ariane van der Straten; Selvi Srinivasan; Ronald S Veazey; Doris Zane Journal: AIDS Res Hum Retroviruses Date: 2021-06 Impact factor: 2.205
Authors: Josep Quer; Maria Buti; Maria Cubero; Jaume Guardia; Rafael Esteban; Juan Ignacio Esteban Journal: Infect Drug Resist Date: 2010-11-23 Impact factor: 4.003
Authors: Robert R Henry; Julio Rosenstock; Douglas K Logan; Thomas R Alessi; Kenneth Luskey; Michelle A Baron Journal: Diabetes Care Date: 2013-05-03 Impact factor: 19.112